{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:17:07Z","timestamp":1786979827532,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00228-026-04117-4","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T02:17:54Z","timestamp":1782353874000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of doravirine\/islatravir for the treatment of HIV-1: a systematic review and meta-analysis of randomized controlled trials with GRADE assessment"],"prefix":"10.1007","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8409-5526","authenticated-orcid":false,"given":"Mohammed R.","family":"Abdeldayem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5346-6976","authenticated-orcid":false,"given":"Ahmed","family":"Elsherbeeny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4212-2424","authenticated-orcid":false,"given":"Ahmad","family":"Beddor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"issue":"2","key":"4117_CR1","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.clindermatol.2024.02.001","volume":"42","author":"S Payagala","year":"2024","unstructured":"Payagala S, Pozniak A (Feb. 2024) The global burden of HIV. Clin Dermatol 42(2):119\u2013127.Feb.https:\/\/doi.org\/10.1016\/j.clindermatol.2024.02.001","journal-title":"Clin Dermatol"},{"key":"4117_CR2","doi-asserted-by":"publisher","unstructured":"Lu Y et al (1928) Global and regional disease burden of HIV\/AIDS from 1990 to 2021 and projections to 2030., BMC Public Health, 25, 1, May 2025. https:\/\/doi.org\/10.1186\/s12889-025-23121-4","DOI":"10.1186\/s12889-025-23121-4"},{"key":"4117_CR3","doi-asserted-by":"publisher","unstructured":"Magomere E et al (2025) The Confluence of HIV-1 and HIV-2: Implications for Disease Progression and Insights for Therapy., Int. J. Microbiol, 3145677, Jul. 2025. https:\/\/doi.org\/10.1155\/ijm\/3145677","DOI":"10.1155\/ijm\/3145677"},{"key":"4117_CR4","doi-asserted-by":"publisher","unstructured":"Fanjul F et al (Oct. 2025) HIV Therapy: The Latest Developments in Antiviral Drugs-A Scoping Review. Biomedicines 13(11). https:\/\/doi.org\/10.3390\/biomedicines13112629","DOI":"10.3390\/biomedicines13112629"},{"key":"4117_CR5","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1001\/jama.2024.24543","volume":"333","author":"RT Gandhi","year":"2025","unstructured":"Gandhi RT et al (2025) Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society-USA Panel., JAMA, 333(7):609\u2013628, Feb. https:\/\/doi.org\/10.1001\/jama.2024.24543","journal-title":"JAMA"},{"issue":"4","key":"4117_CR6","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1007\/s40506-019-00203-7","volume":"11","author":"A Kolakowska","year":"2019","unstructured":"Kolakowska A, Maresca AF, Collins IJ, Cailhol J (2019) Update on adverse effects of HIV integrase inhibitors. Curr Treat Options Infect Dis 11(4):372\u2013387. https:\/\/doi.org\/10.1007\/s40506-019-00203-7","journal-title":"Curr Treat Options Infect Dis"},{"issue":"12","key":"4117_CR7","doi-asserted-by":"publisher","first-page":"e868","DOI":"10.1016\/S2352-3018(22)00249-1","volume":"9","author":"KM Gibas","year":"2022","unstructured":"Gibas KM, Dec (2022) Two-drug regimens for HIV treatment. Lancet HIV 9(12):e868\u2013e883. https:\/\/doi.org\/10.1016\/S2352-3018(22)00249-1","journal-title":"Lancet HIV"},{"issue":"9","key":"4117_CR8","doi-asserted-by":"publisher","first-page":"e660","DOI":"10.1016\/S2352-3018(25)00127-4","volume":"12","author":"SM McCluskey","year":"2025","unstructured":"McCluskey SM, Gandhi M (2025) Predictors of treatment-emergent resistance to dolutegravir. Lancet HIV 12(9):e660\u2013e663. Sep. https:\/\/doi.org\/10.1016\/S2352-3018(25)00127-4","journal-title":"Lancet HIV"},{"key":"4117_CR9","unstructured":"Organization WH (2024) HIV drug resistance brief report 2024. World Health Organization, p 46"},{"issue":"1","key":"4117_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/14656566.2024.2440000","volume":"26","author":"V Williams","year":"2025","unstructured":"Williams V, Cory TJ, Jan (2025) Doravirine\/islatravir for the treatment of HIV. Expert Opin Pharmacother 26(1):9\u201315. https:\/\/doi.org\/10.1080\/14656566.2024.2440000","journal-title":"Expert Opin Pharmacother"},{"issue":"15","key":"4117_CR11","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1007\/s40265-018-0993-4","volume":"78","author":"ED Deeks","year":"2018","unstructured":"Deeks ED, Oct (2018) Doravirine: first global approval. Drugs 78(15):1643\u20131650. https:\/\/doi.org\/10.1007\/s40265-018-0993-4","journal-title":"Drugs"},{"key":"4117_CR12","doi-asserted-by":"publisher","unstructured":"Sch\u00fcrmann D, Lancet HIV et al (2020) 7, 3, pp. e164\u2013e172, Mar. https:\/\/doi.org\/10.1016\/S2352-3018(19)30372-8","DOI":"10.1016\/S2352-3018(19)30372-8"},{"issue":"10528","key":"4117_CR13","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S0140-6736(25)01948-8","volume":"407","author":"AE Colson","year":"2026","unstructured":"Colson AE et al (2026) Switch to fixed-dose doravirine (100 mg) and islatravir (0\u00b725 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial. Lancet 407(10528):611\u2013621. https:\/\/doi.org\/10.1016\/S0140-6736(25)01948-8","journal-title":"Lancet"},{"key":"4117_CR14","doi-asserted-by":"publisher","unstructured":"Mills AM (Jun et al (eds) (2024) Switch to fixed-dose doravirine (100 mg) with islatravir (0\u00b775 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial. Lancet HIV 11(6):e357\u2013e368. https:\/\/doi.org\/10.1016\/S2352-3018(24)00030-4","DOI":"10.1016\/S2352-3018(24)00030-4"},{"issue":"6","key":"4117_CR15","doi-asserted-by":"publisher","first-page":"e369","DOI":"10.1016\/S2352-3018(24)00031-6","volume":"11","author":"J-M Molina","year":"2024","unstructured":"Molina J-M et al (2024) Switch to fixed-dose doravirine (100 mg) with islatravir (0\u00b775 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial. Lancet HIV 11(6):e369\u2013e379. https:\/\/doi.org\/10.1016\/S2352-3018(24)00031-6","journal-title":"Lancet HIV"},{"issue":"10528","key":"4117_CR16","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/S0140-6736(25)01945-2","volume":"407","author":"C Orkin","year":"2026","unstructured":"Orkin C et al (2026) Switch to fixed-dose doravirine (100 mg) and islatravir (0\u00b725 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial. Lancet 407(10528):599\u2013610. https:\/\/doi.org\/10.1016\/S0140-6736(25)01945-2","journal-title":"Lancet"},{"issue":"2","key":"4117_CR17","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1093\/cid\/ciaf077","volume":"81","author":"JK Rockstroh","year":"2025","unstructured":"Rockstroh JK et al (2025) Sep., Doravirine\/Islatravir (100\/0.75 mg) Once-Daily Compared With Bictegravir\/Emtricitabine\/Tenofovir Alafenamide as Initial HIV-1 Treatment: 48-Week Results From a Phase 3, Randomized, Controlled, Double-Blind, Noninferiority Trial. Clin Infect Dis 81(2):322\u2013332. https:\/\/doi.org\/10.1093\/cid\/ciaf077","journal-title":"Clin Infect Dis"},{"key":"4117_CR18","doi-asserted-by":"publisher","unstructured":"Rockstroh JK et al (2026) Fixed-dose daily doravirine (100\u00a0mg) with islatravir (0\u00b725\u00a0mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial., Lancet HIV, Feb. https:\/\/doi.org\/10.1016\/S2352-3018(26)00033-0","DOI":"10.1016\/S2352-3018(26)00033-0"},{"issue":"1","key":"4117_CR19","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan-a web and mobile app for systematic reviews. Syst Rev 5(1):210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4","journal-title":"Syst Rev"},{"key":"4117_CR20","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Aug (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"issue":"1","key":"4117_CR21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","volume":"12","author":"LA McGuinness","year":"2021","unstructured":"McGuinness LA, Higgins JPT (2021) Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods 12(1):55\u201361. https:\/\/doi.org\/10.1002\/jrsm.1411","journal-title":"Res Synth Methods"},{"issue":"4","key":"4117_CR22","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G (2019) How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health 22(4):153\u2013160. https:\/\/doi.org\/10.1136\/ebmental-2019-300117","journal-title":"Evid Based Ment Health"},{"issue":"7650","key":"4117_CR23","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336(7650):924\u2013926. Apr https:\/\/doi.org\/10.1136\/bmj.39489.470347.AD","journal-title":"BMJ"},{"issue":"2","key":"4117_CR24","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s15010-021-01687-6","volume":"50","author":"A Sjaarda","year":"2022","unstructured":"Sjaarda A, Bernstein A, Sparks A, Saber S, Siegel M (2022) Comparison of weight gain after antiretroviral switch to integrase strand transfer inhibitor or tenofovir alafenamide-based therapy. Infection 50(2):407\u2013412. https:\/\/doi.org\/10.1007\/s15010-021-01687-6","journal-title":"Infection"},{"issue":"1","key":"4117_CR25","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/QAI.0000000000003101","volume":"92","author":"FJ Palella","year":"2023","unstructured":"Palella FJ et al (2023) Weight gain and metabolic effects in persons with HIV who switch to ART regimens containing integrase inhibitors or tenofovir alafenamide. J Acquir Immune Defic Syndr 92(1):67\u201375. https:\/\/doi.org\/10.1097\/QAI.0000000000003101","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"9","key":"4117_CR26","doi-asserted-by":"publisher","first-page":"e0045824","DOI":"10.1128\/aac.00458-24","volume":"68","author":"X Zang","year":"2024","unstructured":"Zang X, (2024) Intracellular islatravir-triphosphate half-life supports extended dosing intervals. Antimicrob Agents Chemother 68(9):e0045824. Sep https:\/\/doi.org\/10.1128\/aac.00458-24","journal-title":"Antimicrob Agents Chemother"},{"key":"4117_CR27","doi-asserted-by":"publisher","unstructured":"Maas BM et al (2026) P-344. Modeling Confirms Islatravir 0.25\u00a0mg Administered Daily Has No Adverse Effect on Total Lymphocyte or CD4\u2009+\u2009T-cell Counts in People Living with HIV, Open Forum Infect. Dis., 13, Supplement_1, Jan. https:\/\/doi.org\/10.1093\/ofid\/ofaf695.562","DOI":"10.1093\/ofid\/ofaf695.562"},{"issue":"1","key":"4117_CR28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/QCO.0000000000000616","volume":"33","author":"AR Eckard","year":"2020","unstructured":"Eckard AR, McComsey GA (2020) Weight gain and integrase inhibitors. Curr Opin Infect Dis 33(1):10\u201319 Feb. 10.1097\/QCO.0000000000000616 https:\/\/doi.org\/10.1097\/QCO.0000000000000616","journal-title":"Curr Opin Infect Dis"},{"issue":"6","key":"4117_CR29","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s11904-024-00708-x","volume":"21","author":"S Savinelli","year":"2024","unstructured":"Savinelli S, Newman E, Mallon PWG (2024) Metabolic Complications Associated with Use of Integrase Strand Transfer Inhibitors (InSTI) for the Treatment of HIV-1 Infection: Focus on Weight Changes, Lipids, Glucose and Bone Metabolism. Curr HIV\/AIDS Rep 21(6):293\u2013308. https:\/\/doi.org\/10.1007\/s11904-024-00708-x","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"2","key":"4117_CR30","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1358\/dot.2020.56.2.3109966","volume":"56","author":"R Talwani","year":"2020","unstructured":"Talwani R, Temesgen Z, Feb (2020) Doravirine: a new non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection. Drugs Today 56(2):113\u2013124. https:\/\/doi.org\/10.1358\/dot.2020.56.2.3109966","journal-title":"Drugs Today"},{"issue":"12","key":"4117_CR31","doi-asserted-by":"publisher","first-page":"169100","DOI":"10.1016\/j.jmb.2025.169100","volume":"437","author":"N Zalenski","year":"2025","unstructured":"Zalenski N, Jun (2025) Kinetic Investigation of Resistance to Islatravir Conferred by Mutations in HIV-1 Reverse Transcriptase. J Mol Biol 437(12):169100. https:\/\/doi.org\/10.1016\/j.jmb.2025.169100","journal-title":"J Mol Biol"},{"key":"4117_CR32","doi-asserted-by":"publisher","unstructured":"Byun H, Papathanasopoulos MA, Steegen K, Basson AE (Dec. 2024) Thymidine Analogue Mutations with M184V Significantly Decrease Phenotypic Susceptibility of HIV-1 Subtype C Reverse Transcriptase to Islatravir. Viruses 16(12). https:\/\/doi.org\/10.3390\/v16121888","DOI":"10.3390\/v16121888"},{"issue":"2","key":"4117_CR33","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s40121-024-01103-0","volume":"14","author":"J Fraysse","year":"2025","unstructured":"Fraysse J, Feb (2025) Real-World Effectiveness and Tolerability of Dolutegravir and Lamivudine 2-Drug Regimen in People Living with HIV: Systematic Literature Review and Meta-Analysis. Infect Dis Ther 14(2):357\u2013383. https:\/\/doi.org\/10.1007\/s40121-024-01103-0","journal-title":"Infect Dis Ther"},{"issue":"33","key":"4117_CR34","doi-asserted-by":"publisher","first-page":"e43558","DOI":"10.1097\/MD.0000000000043558","volume":"104","author":"A Doblado-Maldonado","year":"2025","unstructured":"Doblado-Maldonado A et al (2025) Dolutegravir\u2009+\u2009lamivudine effectiveness and tolerability in real-world cohorts with HIV-1 across Asia and South America: A systematic literature review. Med (Baltim) 104(33):e43558. https:\/\/doi.org\/10.1097\/MD.0000000000043558","journal-title":"Med (Baltim)"},{"key":"4117_CR35","doi-asserted-by":"publisher","unstructured":"Llibre JM et al (Sep. 2025) Emergent Human Immunodeficiency Virus Type 1 (HIV-1) Drug Resistance in Randomized Trials of Contemporary Antiretroviral Regimens. Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/ciaf471","DOI":"10.1093\/cid\/ciaf471"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04117-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04117-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04117-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T07:57:28Z","timestamp":1783929448000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04117-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["4117"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04117-4","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"1 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None declared.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This systematic review and meta-analysis did not involve original data from the participant sample; thus, ethical approval was not required. The study was registered in PROSPERO (CRD420261331242).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"188"}}